戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 enza B, two respiratory syncytial virus, one parainfluenza).
2 ommon viral infections such as influenza and parainfluenza.
3 onse to a cluster of hospital-acquired human parainfluenza 3 virus (HPIV3) infections at a children's
4 nation respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal
5 oped antibodies to cytomegalovirus (CMV) and parainfluenza 3.
6 gainst multiple domains of the paramyxovirus parainfluenza 5 (PIV5) pre- and postfusion F and HN.
7                                              Parainfluenza and coronaviruses were also more common am
8 -derived peptide sequence that inhibits both parainfluenza and Nipah viruses, to investigate the infl
9    Besides influenza A and RSV, influenza B, parainfluenza and norovirus may also contribute substant
10  for influenza, respiratory syncytial virus, parainfluenza, and adenovirus infection.
11 hat fuse at the cell surface, including HIV, parainfluenza, and henipaviruses.
12 95% confidence interval [CI], 1.02-4.69) and parainfluenza-ARI (AOR, 1.86; 95% CI, 1.15-3.01), when c
13                                Influenza and parainfluenza ARIs appeared to facilitate pneumococcal a
14 ate an etiologic role, whereas detections of parainfluenza, coronaviruses, rhinovirus, and adenovirus
15 luenza B, respiratory syncytial virus (RSV), parainfluenza, enterovirus, rotavirus, norovirus, Campyl
16                Crystal structures of related parainfluenza F glycoproteins have revealed a large conf
17 quely broad spectrum antiviral activity of a parainfluenza F-derived peptide sequence that inhibits b
18 rhinovirus, respiratory syncytial virus, and parainfluenza has been known for many years.
19 d, particularly in relation to influenza and parainfluenza infections of the respiratory tract.
20                 Respiratory syncytial virus, parainfluenza, influenza, and adenovirus accounted for 2
21       Lower-respiratory-tract infection with parainfluenza (odds ratio [OR], 17.9 [95% confidence int
22 flammation and respiratory death after mouse parainfluenza or human influenza virus infection.
23 nts with influenza (A, 11; B, 4) and 24 with parainfluenza (para1, 7; para2, 2; para3, 15).
24 monia was diagnosed in 10 (5 influenza and 5 parainfluenza) patients, and concurrent bacterial pneumo
25 gle-lung 25, double-lung 14) of influenza or parainfluenza respiratory viral infection were identifie
26                                Influenza and parainfluenza respiratory viral infections are associate
27 ically important viruses, such as influenza, parainfluenza, respiratory syncytial virus (RSV) and Ebo
28 nd early viral exposure to 3 common viruses (parainfluenza, respiratory syncytial virus, and picornav
29 itis virus, measles, mumps, metapneumovirus, parainfluenza, rotavirus, respiratory syncytial virus, a
30                            Similarly, murine parainfluenza (Sendai) respiratory viral infection cause
31                                    For human parainfluenza type 3 (HPIV3), one bifunctional site on H
32      A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45
33 In this study the solution dynamics of human parainfluenza type 3 hemagglutinin-neuraminidase (HN) ha
34 ubjects into respiratory syncytial virus and parainfluenza type 3 vaccine trials when subjects were s
35          A recombinant chimeric bovine/human parainfluenza type 3 virus (rB/HPIV3) vector expressing
36                                    For human parainfluenza type 3, one bifunctional site on HN can ca
37  Neu5Ac2en derivatives that target the human parainfluenza type-1 hemagglutinin-neuraminidase protein
38 alic acid-based inhibitors that target human parainfluenza type-1 hemagglutinin-neuraminidase.
39  vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respirator
40 ke (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as
41 canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPIV), respiratory disease was ende
42 V-respiratory syncytial virus (RSV) or human parainfluenza virus (HPIV) coinfections had wheezing tha
43                                    The human parainfluenza virus (hPIV) hemagglutinin-neuraminidase (
44 presence of the second binding site on human parainfluenza virus (hPIV) type 1, 2, and 3 and Sendai v
45 es, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (h
46 (23), human herpesvirus (HHV)-6B (10), human parainfluenza virus (HPIV)-2 (3), HPIV-3 (1), and human
47 for RSV (n = 35), 2.6 x 10(6) copies/mL; for parainfluenza virus (n = 35), 4.9 x 10(7) copies/mL; for
48 rs mutations in the P/V gene from the canine parainfluenza virus (P/V-CPI(-)) is a potent inducer of
49        Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens
50                                              Parainfluenza virus (PIV) commonly infects patients foll
51                            RSV F and related parainfluenza virus (PIV) F proteins are cleaved by furi
52                                              Parainfluenza virus (PIV) in humans is associated with b
53      Data on characteristics and outcomes of parainfluenza virus (PIV) infections in these patients a
54                                              Parainfluenza virus (PIV) is a negative-sense single-str
55 ually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3.
56 mens), followed by human rhinovirus (17.8%); parainfluenza virus (PIV) types 1-4 (7.5%); enterovirus
57 sting for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by
58 us (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metap
59 (HN, residues 37 to 56) of the paramyxovirus parainfluenza virus (PIV5), a region of the HN stalk tha
60  naturally occurring SV5 variant Wake Forest parainfluenza virus (WF-PIV) activates the synthesis of
61 detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus 1 (PIV-1), PIV-2, and PIV-3, and res
62 l virus (RSV), human metapneumovirus (HMPV), parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and a
63 hese are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5
64    Simian virus 5 (SV5) targets STAT1, human parainfluenza virus 2 targets STAT2, and mumps virus tar
65 ith respiratory syncytial virus (RSV), human parainfluenza virus 3 (HPIV-3), and influenza virus on t
66          We previously reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhi
67 titatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations
68 yxoviruses, such as Nipah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mump
69                                              Parainfluenza virus 3 (PIV-3) infection is highly restri
70         The majority of this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).
71 c fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been eval
72                           The secreted human parainfluenza virus 3 F forms a trimer with distinct hea
73               However, we found that a human parainfluenza virus 3 F-peptide is more effective at inh
74 eaved ectodomain of the paramyxovirus, human parainfluenza virus 3 fusion (F) protein, a member of th
75  homologous HN protein, as well as NDV-human parainfluenza virus 3 HN chimeras.
76 ection but similar to that for influenza and parainfluenza virus 3 infection in all age groups.
77  mumps virus, Newcastle disease virus, human parainfluenza virus 3, and Nipah virus.
78                Antibody titers to RSV, human parainfluenza virus 3, measles, and influenza H1N1, H3N2
79  cell lines with Sendai virus (SeV) or human parainfluenza virus 3, two prototypic paramyxoviruses, c
80 dence similar to that of influenza virus and parainfluenza virus 3.
81      Putative viral pathogens included human parainfluenza virus 4 (aOR 9.3, P = .12), human bocaviru
82 rus [EV], 118; bocavirus, 8; coronavirus, 7; parainfluenza virus 4, 4; Mycoplasma pneumoniae, 1).
83 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix
84                                              Parainfluenza virus 5 (PIV5) activates and is neutralize
85                      For the paramyxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP inter
86 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus
87     In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/
88                            The paramyxovirus parainfluenza virus 5 (PIV5) enters cells by fusion of t
89 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural
90  Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s
91 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid
92                                              Parainfluenza virus 5 (PIV5) HN exists as a noncovalent
93                                              Parainfluenza virus 5 (PIV5) is a member of the Paramyxo
94                                              Parainfluenza virus 5 (PIV5) is a promising viral vector
95                                              Parainfluenza virus 5 (PIV5) is a prototypical paramyxov
96                                              Parainfluenza virus 5 (PIV5) is an appealing vector for
97                                              Parainfluenza virus 5 (PIV5) is an enveloped, single-str
98                             The P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of
99                                              Parainfluenza virus 5 (PIV5) is thought to contribute to
100     To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot
101        In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glyco
102 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi
103                              Preparations of parainfluenza virus 5 (PIV5) that are potent activators
104 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n
105 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s
106                    We tested the recombinant parainfluenza virus 5 (PIV5) vectors expressing RSV glyc
107 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.
108     The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u
109 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.
110                                              Parainfluenza virus 5 (PIV5), a paramyxovirus, is not kn
111      Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut
112           Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vec
113                                 Infection by parainfluenza virus 5 (PIV5), a prototypical member of t
114                                              Parainfluenza virus 5 (PIV5), a prototypical paramyxovir
115                                The genome of parainfluenza virus 5 (PIV5), a prototypical paramyxovir
116 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R
117                                              Parainfluenza virus 5 (PIV5), formerly known as simian v
118  that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l
119       The strain diversity of a rubulavirus, parainfluenza virus 5 (PIV5), was investigated by compar
120                 Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidate
121                    We previously generated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate
122              In this study, we evaluated two parainfluenza virus 5 (PIV5)-vectored vaccines expressin
123 he FP of the F protein of the paramyxovirus, parainfluenza virus 5 (PIV5).
124 f the matrix (M) protein of a paramyxovirus, parainfluenza virus 5 (PIV5).
125 -3 as a binding partner for the M protein of parainfluenza virus 5 (PIV5).
126      Similar results were also observed with parainfluenza virus 5 (PIV5).
127 on (F) protein from the paramyxovirus simian parainfluenza virus 5 (SV5) resulted in mutant F protein
128 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter
129 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th
130  Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform
131 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann
132                      Here, a soluble form of parainfluenza virus 5 F was triggered to refold using te
133 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t
134 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable
135 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of
136         By modeling the crystal structure of parainfluenza virus 5 into the density, it is shown that
137                            The paramyxovirus parainfluenza virus 5 mediates membrane merger through i
138 t robust maturation following infection with parainfluenza virus 5 or influenza virus.
139  this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr
140 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo
141 athogens: human respiratory syncytial virus, parainfluenza virus 5, and Sendai virus.
142                                            A parainfluenza virus 5-vectored vaccine expressing the na
143 sequence, FPIV, important for the budding of parainfluenza virus 5.
144 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont
145 or detecting respiratory viruses, especially parainfluenza virus and adenovirus.
146 d five in which the PLx-RVP failed to detect parainfluenza virus and one in which the detection of in
147 ow fever virus, Japanese encephalitis virus, parainfluenza virus and Sendai virus.
148 sociation with age; especially rhinovirus or parainfluenza virus detection showed positive associatio
149                          While type II human parainfluenza virus induces STAT2 degradation, simian vi
150                                  Analysis of parainfluenza virus infection in mice revealed an unexpe
151        We used mouse models of influenza and parainfluenza virus infection to show that intranasally
152 uenza virus, respiratory syncytial virus, or parainfluenza virus infection.
153  in mixed bone marrow chimeric mice during a parainfluenza virus infection.
154  central memory subpopulations to intranasal parainfluenza virus infection.
155 ccine nor clinically effective treatment for parainfluenza virus infection.
156                                              Parainfluenza virus infections did not differentially af
157  to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin
158 ools elicited by nonpersistent influenza and parainfluenza virus infections.
159 iratory syncytial virus, 2 adenovirus, and 1 parainfluenza virus infections.
160  mouse model in which infection with a mouse parainfluenza virus known as Sendai virus (SeV) leads to
161  significance of membrane fusion activity in parainfluenza virus replication and pathogenesis in vivo
162 e (HN) glycoprotein plays a critical role in parainfluenza virus replication.
163                                          The parainfluenza virus simian virus 5 (SV5) is a poor induc
164     Human epithelial cells infected with the parainfluenza virus simian virus 5 (SV5) show minimal ac
165 aring the sequence of MV F with those of the parainfluenza virus SV5 and Newcastle disease virus (NDV
166                        SER virus is a type 5 parainfluenza virus that does not exhibit syncytium form
167 eviously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in
168 e protein or whole virus digests enables the parainfluenza virus to be identified and typed and for i
169 ontact transmission, the predominant mode of parainfluenza virus transmission, was modeled accurately
170 n to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second re
171                                        Human parainfluenza virus type 1 (HPIV1) also causes severe pe
172                 Sendai virus (SeV) and human parainfluenza virus type 1 (hPIV1) are highly similar in
173              We evaluated a version of human parainfluenza virus type 1 (HPIV1) bearing a stabilized
174                  Sendai virus (SV) and human parainfluenza virus type 1 (hPIV1) have genomes consisti
175                                        Human parainfluenza virus type 1 (HPIV1) is a significant caus
176                                        Human parainfluenza virus type 1 (HPIV1) is a significant caus
177                                        Human parainfluenza virus type 1 (HPIV1) is an important respi
178                                        Human parainfluenza virus type 1 (HPIV1) is an important respi
179  respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (HPIV1) to HPIV4 infect virtu
180 onkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced
181 valuation of an attenuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membr
182            Live attenuated recombinant human parainfluenza virus type 1 (rHPIV1) was investigated as
183                            Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to crea
184 ons of the L polymerase of recombinant human parainfluenza virus type 1 (rHPIV1).
185  live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xeno
186  Hamsters immunized with a recombinant human parainfluenza virus type 1 expressing the fusion F prote
187                                        Human parainfluenza virus type 1 is the major cause of croup i
188 secreted from A549 cells infected with Human parainfluenza virus type 2 (HPIV-2) but not from cells i
189                                        Human parainfluenza virus type 2 (HPIV-2), an important pediat
190                                        Human parainfluenza virus type 2 (HPIV2) is the only member of
191 t for association with V proteins from human parainfluenza virus type 2, parainfluenza virus type 5,
192                  The Kansas strain of bovine parainfluenza virus type 3 (BPIV3) is 100- to 1,000-fold
193  doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3).
194                    Entry and fusion of human parainfluenza virus type 3 (HPF3) require the interactio
195 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra
196          The RNA polymerase complex of human parainfluenza virus type 3 (HPIV 3), a member of the fam
197                                        Human parainfluenza virus type 3 (hPIV-3) is a clinically sign
198                                        Human parainfluenza virus type 3 (HPIV-3) is an airborne patho
199 valent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncy
200  respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r
201  respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent
202 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t
203  Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec
204  Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes
205                The genomic promoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis
206 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami
207 t also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami
208 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living
209                    We demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete au
210 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept
211  against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre
212 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low
213                                        Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is
214 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector
215  encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat
216 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope
217                                    For human parainfluenza virus type 3 (HPIV3), the effects of speci
218                                    For human parainfluenza virus type 3 (HPIV3), the receptor binding
219 aminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3).
220  intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3).
221 s), Newcastle disease virus (NDV), and human parainfluenza virus type 3 (HPIV3).
222 In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human P
223                                              Parainfluenza virus type 3 (PIV3) infection led to laryn
224                                              Parainfluenza virus type 3 (PIV3) infections are a major
225                                              Parainfluenza virus type 3 (PIV3) is major pathogen of c
226 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati
227                     A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion
228      A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev
229           We constructed a human recombinant parainfluenza virus type 3 (rPIV3) that expresses enhanc
230                                    For human parainfluenza virus type 3 and many other paramyxoviruse
231 tial innate antiviral response against human parainfluenza virus type 3 and respiratory syncytial vir
232 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family
233                                        Human parainfluenza virus type 3, a mildly cytopathic virus th
234 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl
235 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o
236 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor
237 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi
238  vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r
239  viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems
240  protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express
241 lymphocytic choriomeningitis virus and human parainfluenza virus type 3.
242 ction of interferon (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibitin
243 teins from human parainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus,
244         We investigated the binding of human parainfluenza virus types 1 and 3 (hPIV1 and hPIV3, resp
245 luding influenza virus A, influenza virus B, parainfluenza virus types 1 and 3, respiratory syncytial
246 A and B and human metapneumovirus, and (iii) parainfluenza virus types 1 to 4.
247  virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and P
248 iratory syncytial viruses A and B; and human parainfluenza virus types 1, 2, and 3.
249 iruses, including influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial vir
250 act of respiratory syncytial virus (RSV) and parainfluenza virus URIs on the frequency of AOM caused
251                         C28a HN is the first parainfluenza virus variant found so far to be specifica
252 ple viruses (respiratory syncytial virus and parainfluenza virus) and multiple phenotypes.
253 infected cells (Wake Forest strain of Canine parainfluenza virus) induced IL-8 secretion by a mechani
254 pproach is further demonstrated here for the parainfluenza virus, a virus which can be life threateni
255 tory syncytial virus, human metapneumovirus, parainfluenza virus, and influenza virus) by reverse-tra
256 ents with respiratory syncytial virus (RSV), parainfluenza virus, influenza virus, metapneumovirus (M
257 roviruses, influenza virus, metapneumovirus, parainfluenza virus, rhinovirus, and respiratory syncyti
258 so showed that extraction will be needed for parainfluenza virus, which was only identified correctly
259 tudies we tested the role of CD8+ T cells in parainfluenza virus-induced hyperreactivity and M2R dysf
260 rus, rhinovirus, and influenza virus but not parainfluenza virus.
261 t for lower-respiratory-tract infection with parainfluenza virus; it stabilized during the months aft
262 he hemagglutinin-neuraminidase (HN) of human parainfluenza viruses (hPIV) in vitro and protected mice
263                                        Human parainfluenza viruses (HPIVs) are a common cause of acut
264                                        Human parainfluenza viruses (HPIVs) are among the most common
265 glutinin-neuraminidase (HN) protein of human parainfluenza viruses (hPIVs) both binds (H) and cleaves
266                                        Human parainfluenza viruses (HPIVs) cause widespread respirato
267         The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface
268         The paramyxoviruses, including human parainfluenza viruses (HPIVs), cause a large share of th
269                                              Parainfluenza viruses (PIVs) are one of the most common
270 ed negative for respiratory syncytial virus, parainfluenza viruses (types 1-3), influenza A and B vir
271                   FilmArray RP detected more parainfluenza viruses 1 and 3 than ProParaflu+ (18 versu
272 virus, influenza A virus, influenza B virus, parainfluenza viruses 1 to 3, and respiratory syncytial
273 nfluenza A virus H1-2009, influenza B virus, parainfluenza viruses 1 to 4, respiratory syncytial viru
274  syncytial virus; influenza A and B viruses; parainfluenza viruses 1, 2, 3, and 4; human metapneumovi
275 an respiratory syncytial virus (HRSV); human parainfluenza viruses 1, 2, and 3 (HPIV1, -2, and -3, re
276 piratory syncytial virus, influenza A and B, parainfluenza viruses 1-3, and adenovirus.
277 picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, a
278 in reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human meta
279 lture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses 4a and 4b, and rhinoviruses) and t
280                                              Parainfluenza viruses are a common cause of seasonal res
281                                              Parainfluenza viruses are known to inhibit type I interf
282 protein and nucleocapsid sustain assembly of parainfluenza viruses at the plasma membrane.
283                                  Three human parainfluenza viruses bind to glycans terminating with N
284  (RSV), adenoviruses, influenza viruses, and parainfluenza viruses by use of nested polymerase chain
285                                        Human parainfluenza viruses cause several serious respiratory
286                       Although influenza and parainfluenza viruses commonly cause respiratory tract i
287  Our results illustrate how the particles of parainfluenza viruses efficiently accommodate cargoes of
288                                              Parainfluenza viruses enter host cells by fusing the vir
289                                              Parainfluenza viruses initiate infection by binding to c
290                Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protect
291 ew evidence regarding strategies employed by parainfluenza viruses to effectively circumvent respirat
292 on of 274 of 279 influenza viruses, 33 of 38 parainfluenza viruses, 35 of 51 adenoviruses, and 52 of
293 etapneumovirus, respiratory syncytial virus, parainfluenza viruses, and Haemophilus influenzae being
294 causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encep
295 , which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and huma
296 ruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial virus, huma
297 p of viruses that includes measles virus and parainfluenza viruses.
298 an respiratory syncytial virus and the human parainfluenza viruses.
299 tein subunits play the cell entry concert of parainfluenza viruses.
300 y in all studied age groups; influenza B and parainfluenza were additionally associated in those aged

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top